The Immune System in Cancer
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 250
Special Issue Editor
Interests: cancer; immunotherapy; immuno-oncology; immunology; tumor microenvironment; radiotherapy; radioresistance
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Our current knowledge of the tumor microenvironment (TME) is unprecedented and there’s much to exploit for developing novel and effective therapies against cancer. In particular, immune cells represent a major component of many solid tumors and their activation can lead to effective anti-tumor immunity. The use of cancer vaccines has increased significantly in recent years. Many questions remain unanswered: how can they be effectively combined with other therapies? what are the best most effective means to deliver cancer vaccines? why do some patients respond while others have inherent resistance? how does acquired resistance develop and how to over come it? and what is the underlying biology behind the cross-talk between immune cells and the various components of the TME (tumor cells, endothelial cells, fibroblasts)? By understanding the immune TME, we can begin to answer these questions and address the existing challenges in their application. This special issue, titled "The Immune System in Cancer” will help bridge the existing knowledge gap and provide some answers to these questions. We welcome all types of submissions under this theme related to tumor immunology and the microenvironment.
Prof. Dr. Ayman J. Oweida
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- immunotherapy
- immuno-oncology
- immunology
- tumor microenvironment
